Smaddening Complexity: The Role of Smad3 in Epithelial-Myofibroblast Transition
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Epithelial-mesenchymal transition (EMT) has emerged as a major mechanism in the pathogenesis of organ fibrosis. The epithelium has been proposed to be a significant source of matrix-producing fibroblasts and of myofibroblasts (MFs), a motile and contractile cell type hallmarked by the expression of α-smooth muscle actin (SMA). Importantly, tissue accumulation of MFs shows strong correlation with the severity and progression of fibrotic diseases. The pleiotropic cytokine transforming growth factor-β 1 has been long known as the chief inducer of fibrosis, EMT and MF generation. Accordingly, receptor Smads (Smad2 and particularly Smad3), the direct targets of the activated transforming growth factor-β receptor have been implicated as critical mediators in fibrogenesis and EMT. However, evidence is accumulating that the role of Smad3 is complex and apparently controversial; in fact, Smad3 may differentially affect the various components of EMT, including the loss of epithelial markers (de-epithelialization), the production of extracellular matrix (fibrogenesis) and the expression of SMA (myogenic program). In this review, we revisit the role of Smad3 in epithelial-myofibroblast transition (EMyT). We first summarize the evidence supporting the thesis that Smad3 is a key mediator of EMT and MF generation; next, we present evidence supporting the antithesis that Smad3 is in fact a negative regulator of SMA expression and the activation of the myogenic program in the epithelium; finally, we propose a synthesis, which depicts Smad3 as a timekeeper and context-dependent modulator of EMyT. We suggest that EMyT is composed of an early, mesenchymal, Smad3-promoted phase and a late, myogenic, Smad3-inhibitable phase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804 · cited 2×
“Xu et al., 2009; Zeisberg and Neilson, 2009], the participation of EMT in fibrogenesis in vivo is more controversial.”
BackgroundBiomarkers for epithelial-mesenchymal transitions
Zeisberg, M., & Neilson, E. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36183 · Cited by 2,299
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Formation and function of the myofibroblast during tissue repair
Hinz, B. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700613 · Cited by 1,658 · cited 4×
“MFs can originate from resident fibroblasts, pericytes, bone marrow-derived circulating fibrocytes and monocytes/macrophages [Hinz, 2007; Wynn, 2008].”
BackgroundInfluentialMyofibroblast contraction activates latent TGF-β1 from the extracellular matrix
Wipff, P.-J., Rifkin, D. B., Meister, J.-J., & Hinz, B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704042 · Cited by 1,346 · cited 2×
“…will exert a positive feedback by promoting the development of these costimulatory factors (e.g., it facilitates contact downregulation, contraction, ECM stiffness), and (3) enhanced mechanical tension (e.g., due to matrix stiffness + SMA expression) can activate latent TGF- [Wipff et al., 2007].”
BackgroundActin dynamics control SRF activity by regulation of its coactivator MAL
Miralles, F., Posern, G., Zaromytidou, A.-I., & Treisman, R. (2003) · Cell · doi:10.1016/s0092-8674(03)00278-2 · Cited by 1,327
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response
Ashcroft, G. S., Yang, X., Glick, A. B., Weinstein, M., Letterio, J. J., Mizel, D. E., Anzano, M., Greenwell-Wild, T., Wahl, S. M., Deng, C., et al. (1999) · Nature Cell Biology · doi:10.1038/12971 · Cited by 911 · cited 4×
“For example, Smad3 KO animals exhibit impaired recruitment of and TGF- production by macrophages at the site of injury, and many (albeit not all) of the fibrotic effects were restored by local TGF- addition [Ashcroft et al., 1999].”
BackgroundResultInfluentialModels of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866 · cited 2×
“…pathologies include idiopathic pulmonary fibrosis and other forms of interstitial lung disease, liver cirrhosis, tubulointerstitial fibrosis, glomerulosclerosis, scleroderma and a variety of cardiovascular disorders [Iredale, 2007; Varga and Abraham, 2007; Gharaee-Kermani et al., 2009; Liu, 2010].”
BackgroundLiu, D., Black, B. L., & Derynck, R. (2001) · Genes & Development · doi:10.1101/gad.925901 · Cited by 399 · cited 6×
“Smad3 physically interacts with and thereby inhibits 2 critically important myogenic transcription factors, MyoD [Liu et al., 2001] and myocyte enhancer factor 2 [Liu et al.”
BackgroundInfluentialHinz, B. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0017-1 · Cited by 373 · cited 1×
“…Tamiya et al., 2009; Zheng et al., 2009], enhanced cell contractility or tension [Wipff et al., 2007; Epithelial-Myofibroblast Transition Cells Tissues Organs 2011;193:41–52 43 Gomez et al., 2010], increased matrix stiffness [Hinz, 2009] or the activation of integrins [Kim et al., 2009a, 2009b].”
BackgroundSmad3 Mediates Transforming Growth Factor-β–Induced α-Smooth Muscle Actin Expression
Hu, B., Wu, Z., & Phan, S. H. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0063oc · Cited by 325 · cited 4×
“Second, the effect of Smad3 overexpression on the SMA promoter is fully context dependent: e.g. the stimulatory effect was found in lung fibroblasts [Hu et al., 2003], while Smad3 failed to drive the SMA promoter in the multipotential 10T1/2 cell line [Qiu et al., 2005] and in kidney tubular cells…”
BackgroundResultInfluentialMorita, T., Mayanagi, T., & Sobue, K. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200708174 · Cited by 262
Flanders, K. C., Major, C. D., Arabshahi, A., Aburime, E. E., Okada, M. H., Fujii, M., Blalock, T. D., Schultz, G. S., Sowers, A., Anzano, M. A., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63582-1 · Cited by 167
Tomasek, J. J., McRae, J., Owens, G. K., & Haaksma, C. J. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62353-x · Cited by 101 · cited 1×
“…it is worth noting that in addition to impacting the Smad and MRTF/SRF pathways and their interactions [Elberg et al., 2008; Masszi et al., 2010], TGF- was reported to drive the SMA promoter via the TGF- control element as well [Tomasek et al., 2005], which is a target of Kruppel-like factors.”
Background
Cited by
TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis
Xu, F., Liu, C., Zhou, D., & Zhang, L. (2016) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415627681 · Cited by 756
The mechanical memory of lung myofibroblasts
Balestrini, J. L., Chaudhry, S., Sarrazy, V., Koehler, A., & Hinz, B. (2012) · Integrative Biology · doi:10.1039/c2ib00149g · Cited by 386
TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M., & Ten Dijke, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102157 · Cited by 360
Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family
Katsuno, Y., & Derynck, R. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.02.028 · Cited by 187
cAMP and Epac in the regulation of tissue fibrosis
Insel, P. A., Murray, F., Yokoyama, U., Romano, S., Yun, H., Brown, L., Snead, A., Lu, D., & Aroonsakool, N. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01847.x · Cited by 175
“Smad3 has been proposed to be a critical timer/delayer of development of EMT and to differentially affect various components of EMT (Masszi et al., 2010; Masszi and Kapus, 2011).”
Background
Metadata
- Authors
- Masszi, A., & Kapus, A.
- Venue
- Cells Tissues Organs
- Publisher
- S. Karger AG
- Published
- 2010-11-03
- Volume
- 193
- Issue
- 1-2
- Pages
- 41-52
- ISSN
- 1422-6405 (ISSN-L)
- 1422-6421
- OpenAlex
- W2034955793
- Cited by
- 64
- References
- 15
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.